{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:28:50Z","timestamp":1790270930229,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious disease associated with various antibiotics, which is often misdiagnosed. DIIHA often leads to adverse outcomes, including organ failure and even death. Ceftriaxone is one of the most common drugs that cause DIIHA. This study reports a case of ceftriaxone-induced DIIHA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>A 5-year-old patient diagnosed with community-acquired pneumonia developed a rash on the 5th day of anti-infective treatment with cefazoxime and azithromycin, followed by a rapid decline in hemoglobin levels and the presence of hemoglobin in the urine (hemoglobinuria). Laboratory analysis showed a positive Coombs\u2019 test for the patient. The rash and hematuria subsided after cefazoxime and azithromycin were stopped and symptomatic treatment such as methylprednisolone intravenous infusion, sodium bicarbonate-alkalized urine, enoxaparin sodium anticoagulation, and antiallergic therapy. 5 days later, the child was treated with ceftriaxone for anti-infective therapy because the pneumonia was not healed. During the treatment, the patient suddenly developed itching all over the body, pale face, slightly fast breathing, vomiting, abdominal pain, and low back pain. Immediate cessation of ceftriaxone sodium infusion, continuous nasal catheter oxygen inhalation, normal saline dilatation, and meprednisolone anti-inflammatory and symptomatic treatment of cetirizine were performed. On the evening of the same day, the patient presented with symptoms of wine-colored urine. Laboratory analysis indicated severe anemia and persistent hemolysis, which was considered to autoimmune hemolytic anemia caused by ceftriaxone. After three transfusions and plasma exchange, the patient improved and was discharged from the hospital. One month later, there were no obvious abnormalities in urine analysis, blood routine analysis, reticulocyte analysis, and liver function test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Understanding the patient\u2019s medical history can provide critical information for the diagnosis of DIIHA, and effective management of DIIHA includes immediate discontinuation of suspected drugs, transfusion support, plasma exchange, and symptomatic medication.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1476563","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:21:07Z","timestamp":1741065667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftriaxone-induced immune hemolytic anemia: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaoyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011842","article-title":"A leap in recognizing drug-induced immune hemolytic anemia","volume":"8","author":"Hansen","year":"2024","journal-title":"Blood Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2291075","article-title":"Novel pharmacotherapy for drug-induced immune hemolytic anemia","volume":"24","author":"Barcellini","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1390082","article-title":"Case report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with Malignant rectal cancer","volume":"15","author":"Lou","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2017.177.issue-2","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009801","article-title":"Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study","volume":"8","author":"Maquet","year":"2024","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21307\/immunohematology-2019-098","article-title":"Drug-induced immune hemolytic anemia: the last 30 years of changes","volume":"30","author":"Arndt","year":"2014","journal-title":"Immunohematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/19.088","article-title":"Ceftriaxone-induced hemolytic anemia: A rare case report","volume":"24","author":"Kumar","year":"2020","journal-title":"Perm J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.123465","article-title":"Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation","volume":"17","author":"Shrimali","year":"2013","journal-title":"Indian J Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.7759\/cureus.8660","article-title":"Ceftriaxone-induced immune hemolytic anemia","volume":"49","author":"Neuman","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B11","article-title":"Hemolytic anemia: evaluation and differential diagnosis","volume":"98","author":"Phillips","year":"2018","journal-title":"Am Fam Physician"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.06.004","article-title":"Immune hemolytic anemia associated with drug therapy","volume":"24","author":"Garratty","year":"2010","journal-title":"Blood Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-101","article-title":"Diagnostic pitfalls of drug-induced immune hemolytic anemia","volume":"30","author":"Salama","year":"2014","journal-title":"Immunohematology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2016.1180829","article-title":"Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'","volume":"72","author":"De Wilde","year":"2017","journal-title":"Acta Clin Belg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23218","article-title":"The direct antiglobulin test: a critical step in the evaluation of hemolysis","volume":"87","author":"Zantek","year":"2012","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v63.10","article-title":"Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma","volume":"63","author":"Pecker","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/pai.2014.25.issue-1","article-title":"Adverse drug reactions during ceftriaxone treatment can cause severe hemolysis","volume":"25","author":"Liu","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s001340000598","article-title":"Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature","volume":"26","author":"Seltsam","year":"2000","journal-title":"Intensive Care Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_67_17","article-title":"Severe drug-induced immune hemolysis due to ceftriaxone","volume":"14","author":"Dara","year":"2020","journal-title":"Asian J Transfus Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1476563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:21:10Z","timestamp":1741065670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1476563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1476563"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1476563","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1476563"}}